MwanzoGRTSQ • OTCMKTS
add
Gritstone bio Inc
Bei iliyotangulia
$ 0.021
Bei za siku
$ 0.018 - $ 0.027
Bei za mwaka
$ 0.013 - $ 3.17
Thamani ya kampuni katika soko
2.84M USD
Wastani wa hisa zilizouzwa
35.84M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
OTCMKTS
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 921.00 | -52.89% |
Matumizi ya uendeshaji wa biashara | 7.70M | 14.62% |
Mapato halisi | -23.40M | 33.64% |
Kiwango cha faida halisi | elfu -2.54 | -40.86% |
Mapato kwa kila hisa | -0.16 | 48.39% |
EBITDA | -25.98M | 23.17% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 55.71M | -51.36% |
Jumla ya mali | 142.54M | -35.97% |
Jumla ya dhima | 120.35M | 6.45% |
Jumla ya hisa | 22.19M | — |
hisa zilizosalia | 118.11M | — |
Uwiano wa bei na thamani | 0.11 | — |
Faida inayotokana na mali | -49.31% | — |
Faida inayotokana mtaji | -57.02% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -23.40M | 33.64% |
Pesa kutokana na shughuli | -26.81M | 13.41% |
Pesa kutokana na uwekezaji | elfu -885.00 | -103.60% |
Pesa kutokana na ufadhili | 35.63M | 3,403.74% |
Mabadiliko halisi ya pesa taslimu | 7.94M | 248.24% |
Mtiririko huru wa pesa | -14.40M | 32.03% |
Kuhusu
Gritstone bio is a clinical-stage American biotechnology company which develops cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., and is based in Emeryville, California.
In September 2021 it raised $55.0 million from the sale of 5,000,000 shares.
It started a Phase 1 trial of its self-amplifying mRNA second generation SARS-CoV-2 vaccine, GRT-R910, in the NIHCR Manchester Clinical Research Facility at Manchester Royal Infirmary, in September 2021. This is to explore the ability of GRT-R910 to boost and expand the immunogenicity of AstraZeneca's first-generation COVID-19 vaccine AZD1222 in healthy adults of more than 60 years. It uses lipid nanoparticles to deliver a broad set of antigens against SARS-CoV-2 that includes both stabilized spike protein and highly conserved viral protein regions containing T cell epitopes. Prof. Andrew Ustianowski is the study’s chief investigator.
On 10 November 2021, Gritstone announced positive preclinical data of its second-generation self-amplifying mRNA vaccine against SARS-CoV-2 in non-human primate models. Wikipedia
Ilianzishwa
Ago 2015
Makao Makuu
Tovuti
Wafanyakazi
231
